After completing 13 treatment cycles of IPI-145, subjects may continue to receive additional cycles of IPI-145 until disease progression or unacceptable toxicity. However, to receive additional cycles of IPI-145 beyond 13 cycles, subjects must have evidence of response (CR or PR) according to the IWG criteria1 by the end of Cycle 13.